HBIO
Harvard Bioscience, Inc.
HBIO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over HBIO overall, supported by stronger fundamentals and lower modeled downside.
HBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
HBIO's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HBIO PE Valuation
HBIO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
HBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect HBIO's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over HBIO on the outlook, with more favorable profitability expectations.
HBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.59 | +$9.51 |
| Q2 2026 | -$2.31 | +$10.59 |
| Q1 2026 | -$2.17 | +$10.93 |
| Q4 2025 | -$12.80 | -$10.00 |
| Q3 2025 | -$12.10 | -$8.80 |
| Q2 2025 | -$12.90 | -$10.40 |
| Q1 2025 | -$13.10 | -$11.10 |
| Q4 2024 | -$2.80 | -$2.00 |
HBIO is still losing money, but far less than before: $2.59 per share over the past year, against $13.10 at its worst in early 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over HBIO on earnings quality, reporting a profit while its opponent remains loss making.
HBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.2M | +7.8% |
| Q2 2026 | $22.7M | +11% |
| Q1 2026 | $20.8M | -4.7% |
| Q4 2025 | $23.7M | -3.3% |
| Q3 2025 | $20.6M | -6.3% |
| Q2 2025 | $20.5M | -11% |
| Q1 2025 | $21.8M | -11% |
| Q4 2024 | $24.6M | -13% |
HBIO's revenue is recovering but still below its 2021 peak: $22M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | -6.1 points |
| Q2 2026 | -4.3% | -0.3 points |
| Q1 2026 | -5.7% | +223 points |
| Q4 2025 | 7.2% | +7.2 points |
| Q3 2025 | 1% | +9.5 points |
| Q2 2025 | -4% | +5 points |
| Q1 2025 | -228% | -219 points |
| Q4 2024 | 0% | -1 points |
HBIO's operating margin was −5.2% last quarter, down 6.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over HBIO on profitability, with a higher operating margin.
HBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -234% |
| Q2 2026 | -$363K | -114% |
| Q1 2026 | -$1.1M | -144% |
| Q4 2025 | -$545K | -138% |
| Q3 2025 | $877K | +$2.6M |
| Q2 2025 | $2.7M | +$4.3M |
| Q1 2025 | $2.5M | +226% |
| Q4 2024 | $1.4M | -59% |
HBIO's free cash flow has turned negative after years in the green: −$3M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over HBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
HBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +35K shares |
| 1 year | +2.4% | +105K shares |
| 3 years | +6.8% | +292K shares |
| 5 years | +15% | +582K shares |
| Available history | +21% | +780K shares |
HBIO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.3x | High |
| Q2 2026 | 6.2x | High |
| Q1 2026 | 5.5x | High |
| Q4 2024 | 43.1x | High |
| Q3 2024 | 30.5x | High |
| Q2 2024 | 15.6x | High |
| Q1 2024 | 6.5x | High |
| Q4 2023 | 3.7x | Elevated |
HBIO's net debt is about 10 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over HBIO on leverage, with a lower net debt burden relative to earnings.
HBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 83.0 | Overbought |
HBIO's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HBIO PE vs Healthcare Sector
HBIO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.42 | 9.4% above |
| 20 week MA | $7.52 | 22% above |
| 50 week MA | $6.58 | 40% above |
| 100 week MA | $7.00 | 32% above |
| 200 week MA | $23.1 | 60% below |
HBIO has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 60% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HBIO on trend strength, trading above more of its moving averages.
HBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.4 | $40.8 | +39% |
| 2021 | $40.8 | $71.0 | +74% |
| 2022 | $71.0 | $27.3 | -62% |
| 2023 | $27.3 | $53.5 | +96% |
| 2024 | $53.5 | $19.8 | -63% |
| 2025 | $19.8 | $7.02 | -65% |
| 2026 YTD | $7.02 | $9.21 | +31% |
HBIO is up 31% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HBIO on returns for 2026, with the stronger performance.